Resilience Approved for $410M Financing from the Department of Defense, in Partnership with the Development Finance Corporation, to Establish Resilient Biomanufacturing Capacity
National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, today announced that it has signed a finance agreement for $410 million in long-term loan financing from the U.S. Department of Defense (DoD), working with the U.S. International Development Finance Corporation (DFC).
- National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, today announced that it has signed a finance agreement for $410 million in long-term loan financing from the U.S. Department of Defense (DoD), working with the U.S. International Development Finance Corporation (DFC).
- The loan financing will support Resilience’s mission to establish significant domestic, end-to-end biomanufacturing capacity and capabilities for biologics (antibodies, proteins, multi-specifics), vaccines, and nucleic acids (including mRNA).
- Part of the financing will support the implementation of innovative manufacturing platforms and technologies that aim to reduce cost, strengthen the domestic supply chain, and increase the speed of vaccine supply.
- "The lack of growth and innovation in domestic biomanufacturing was one critical vulnerability that impacted preparedness during the COVID-19 pandemic.